0000000000676913

AUTHOR

Anna Maria Cattelan

0000-0003-2869-2945

showing 2 related works from this author

Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy

2015

In 2012, we conducted a retrospective cross-sectional study to assess the number of people living with HIV linked to care and, among these, the number of people on antiretroviral therapy. The health authority in each of the 20 Italian Regions provided the list of Public Infectious Diseases Clinics providing antiretroviral therapy and monitoring people with HIV infection. We asked every Public Infectious Diseases Clinic to report the number of HIV-positive people diagnosed and linked to care and the number of those on antiretroviral therapy during 2012. In 2012, 94,146 people diagnosed with HIV and linked to care were reported. The majority were males (70.1%), Italians (84.4%), and aged betw…

AdultMalePediatricsmedicine.medical_specialtyImmunology; Infectious Diseases; VirologySettore MED/17 - Malattie InfettiveEpidemiologyCross-sectional studyImmunologyHuman immunodeficiency virus (HIV)MEDLINEHIV Infectionsmedicine.disease_causeAdult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Prevalence; Retrospective StudiesVirologymedicinePrevalenceHumansHIV InfectionHIV prevalence ItalyRetrospective StudiesCross-Sectional StudieAdult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Prevalence; Retrospective Studies; Immunology; Virology; Infectious Diseasesbusiness.industryTransmission (medicine)HIVRetrospective cohort studyMiddle AgedHiv prevalenceNorthern italyCD4 Lymphocyte CountCross-Sectional StudiesInfectious DiseasesAnti-Retroviral AgentsItalyAnti-Retroviral AgentFemalebusinessViral loadHumanDemography
researchProduct

Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-li…

2020

Objectives: We evaluated the efficacy and safety of dalbavancin in ABSSSI and ‘other sites’ infections’ (OTA). Methods: Observational study involving 11 Italian hospitals including patients that received ≥1 dose of dalbavancin in 2016–2019. The outcome was end-of-treatment efficacy and safety in ABSSSI and OTA in a real-life setting. Results: 206 patients enrolled (males 50%, median age 62 [IQR 50–76] years), 60.2% ABSSSI, 39.8% OTA. 69.7% ABSSSI vs 90.7% OTA (p = 0.003) and 46.3% ABSSSI vs 37.2% OTA (p = 0.786) received previous and concomitant antibiotics, respectively. 82.5% reached clinical cure. Eleven (5.4%) patients had non-serious adverse events (AE). OTA patients showed longer hosp…

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialtyGram-positive infection030106 microbiologyReal life settingMicrobiology03 medical and health sciences0302 clinical medicineVirologyInternal medicineAntibiotic therapymedicineantibiotic therapyHumansacute bacterial skin and skin structure infection030212 general & internal medicineAgedRetrospective Studiesbusiness.industryDalbavancinOff-Label UseSkin Diseases BacterialMiddle Agedacute bacterial skin and skin structure infectionsAnti-Bacterial Agentssecond-generation lipoglycopeptide antibioticsHospitalizationacute bacterial skin and skin structure infections; antibiotic therapy; dalbavancin; Gram-positive infections; second-generation lipoglycopeptide antibioticsInfectious DiseasesItalyAcute DiseaseSkin structureObservational studyFemalesecond-generation lipoglycopeptide antibiotics.TeicoplaninbusinessGram-positive infectionsdalbavancin
researchProduct